Logo image of LCI

LANNETT CO INC (LCI) Stock Fundamental Analysis

NYSE:LCI - New York Stock Exchange, Inc. - US5160122009 - Common Stock - Currency: USD

0.6855  +0.03 (+3.86%)

Fundamental Rating

1

Taking everything into account, LCI scores 1 out of 10 in our fundamental rating. LCI was compared to 193 industry peers in the Pharmaceuticals industry. LCI may be in some trouble as it scores bad on both profitability and health. LCI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year LCI has reported negative net income.
In the past year LCI has reported a negative cash flow from operations.
In the past 5 years LCI reported 4 times negative net income.
Of the past 5 years LCI 4 years had a positive operating cash flow.
LCI Yearly Net Income VS EBIT VS OCF VS FCFLCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M -300M

1.2 Ratios

The profitability ratios for LCI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LCI Yearly ROA, ROE, ROICLCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 1K

1.3 Margins

LCI has a Gross Margin of 12.26%. This is comparable to the rest of the industry: LCI outperforms 52.97% of its industry peers.
In the last couple of years the Gross Margin of LCI has declined.
The Profit Margin and Operating Margin are not available for LCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
LCI Yearly Profit, Operating, Gross MarginsLCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50

2

2. Health

2.1 Basic Checks

LCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
LCI has more shares outstanding than it did 1 year ago.
The debt/assets ratio for LCI is higher compared to a year ago.
LCI Yearly Shares OutstandingLCI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LCI Yearly Total Debt VS Total AssetsLCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.51, we must say that LCI is in the distress zone and has some risk of bankruptcy.
LCI has a Altman-Z score (-1.51) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC4.16%
LCI Yearly LT Debt VS Equity VS FCFLCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M 800M

2.3 Liquidity

LCI has a Current Ratio of 2.23. This indicates that LCI is financially healthy and has no problem in meeting its short term obligations.
LCI's Current ratio of 2.23 is on the low side compared to the rest of the industry. LCI is outperformed by 63.01% of its industry peers.
LCI has a Quick Ratio of 1.39. This is a normal value and indicates that LCI is financially healthy and should not expect problems in meeting its short term obligations.
LCI's Quick ratio of 1.39 is on the low side compared to the rest of the industry. LCI is outperformed by 68.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.39
LCI Yearly Current Assets VS Current LiabilitesLCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

1

3. Growth

3.1 Past

The earnings per share for LCI have decreased strongly by -129.18% in the last year.
LCI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.09%.
LCI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.78% yearly.
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%

3.2 Future

LCI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.51% yearly.
Based on estimates for the next years, LCI will show a decrease in Revenue. The Revenue will decrease by -0.68% on average per year.
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LCI Yearly Revenue VS EstimatesLCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
LCI Yearly EPS VS EstimatesLCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LCI. In the last year negative earnings were reported.
Also next year LCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCI Price Earnings VS Forward Price EarningsLCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCI Per share dataLCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.42%
EPS Next 3Y8.51%

0

5. Dividend

5.1 Amount

No dividends for LCI!.
Industry RankSector Rank
Dividend Yield N/A

LANNETT CO INC

NYSE:LCI (4/19/2023, 8:06:04 PM)

0.6855

+0.03 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-01 2023-02-01/amc
Earnings (Next)05-02 2023-05-02/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners133.44%
Ins Owner Change0%
Market Cap7.38M
Analysts46.67
Price Target4.08 (495.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.25%
Min EPS beat(2)8.61%
Max EPS beat(2)17.89%
EPS beat(4)4
Avg EPS beat(4)9.07%
Min EPS beat(4)4.48%
Max EPS beat(4)17.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.34%
Min Revenue beat(2)8.96%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)2.45%
Min Revenue beat(4)-7.25%
Max Revenue beat(4)9.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-294.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-283.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.44
EYN/A
EPS(NY)-5.49
Fwd EYN/A
FCF(TTM)-5.56
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS28.66
BVpS-29
TBVpS-31.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.26%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 1.39
Altman-Z -1.51
F-Score2
WACC4.16%
ROIC/WACCN/A
Cap/Depr(3y)48.49%
Cap/Depr(5y)64.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A
EBIT growth 1Y-129.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.64%
EBIT Next 3Y40.89%
EBIT Next 5YN/A
FCF growth 1Y-354.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.84%
OCF growth 3YN/A
OCF growth 5YN/A